All In Biotech

NDA 209184 · Merz

Inbrija

Levodopa · Inhalation · Aromatic Amino Acid

Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Dec 21, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

489

127 Phase 3, 26 recruiting

FAERS reports

12,511

6,194 serious, 1,389 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 20, 2026.

INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is an aromatic amino acid indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa ( 1 )

Mechanism: Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • INBRIJA · LEVODOPA 42MG · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Levodopa" as an intervention, any sponsor and status, largest first.

All 489 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • cough2,350
  • drug ineffective1,474
  • parkinson^s disease1,081
  • condition aggravated818
  • dyskinesia785
  • death733
  • fall732
  • device issue721
  • hallucination674
  • product residue present571
  • tremor554
  • device difficult to use523

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200436
200538
200665
200769
2008104
200993
2010120
2011109
2012116
2013147
2014200
2015273
2016259
2017357
2018507
20191,516
20201,885
20212,286
20221,630
2023507
2024531
2025662
20261,001

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Inbrija (Levodopa)

2024 spending

$27.7M

Beneficiaries

2,431

8,665 claims

Per beneficiary

$11,390

$20.50 per unit

View as table
YearSpending
2020$20,360,135
2021$25,158,886
2022$23,058,779
2023$27,040,847
2024$27,688,440

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,162 on PubMed

Sponsor: Merz

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.